| | | |

Extending Mesothelioma Survival with Chemotherapy

ByAlex Strauss

In the continued quest to improve the effectiveness of chemotherapy treatment for malignant pleural mesothelioma, two new studies have been published this week on the effectiveness of adding additional drugs to the standard combination.

The majority of patients who receive a mesothelioma diagnosis will have treatment that includes chemotherapy. According to data from the National Cancer Institute’s SEER database, the chemotherapy regimen prescribed most often for mesothelioma is a combination of pemetrexed (Alimta) and cisplatin or carboplatin. Approximately 67 percent of mesothelioma patients who receive chemotherapy have this combination.

Unfortunately, even the standard chemotherapy combination has not been shown to extend mesothelioma survival by more that a few months. Scientists are continually looking for ways to make it more effective.

Attacking Mesothelioma Tumors at the Vascular Level

One recently tested approach involved adding an experimental drug called NGR-hTNF to the mix. NGR-hTNF in a novel therapeutic agent that specifically targets tumor blood vessels. In addition to being fast-growing, mesothelioma tumors are highly vascularized.

The theory is that disrupting the blood flow that feeds a mesothelioma tumor could make it more susceptible to attack with chemotherapy drugs.

 

In a double blind, placebo-controlled, phase 3 trial conducted at 41 centers in 12 countries, doctors gave NGR-hTNF to 400 mesothelioma patients whose cancer had come back after standard chemotherapy.

The drug was given weekly by infusion along with one of several different chemotherapy drugs (gemcitabine, vinorelbine, or doxorubicin), at the doctor’s discretion.

Although NGR-hTNF did not cause any more serious side effects or deaths than the other chemotherapy drugs, it also did not appear to extend survival.

“At the cutoff date, the median follow-up was 18.7 months and overall survival did not differ between the two treatment groups (median 8.5 months in the NGR-hTNF group vs 8 months in the placebo group),” states the report summary published online by Lancet Oncology this week.

Gemcitabine May Work Better During Surgery

Another drug getting attention from the mesothelioma community this week is gemcitabine and the news appears to be somewhat better. Gemcitabine (Gemzar) is most often used to treat cancer of the bladder, ovary, breast, pancreas and non-small cell lung cancer.

In the new study, renowned mesothelioma surgeon Dr. David Sugarbaker of Baylor College of Medicine, along with colleagues  at Brigham and Women’s, Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center in Boston, added gemcitabine to cisplatin as part of  heated intraoperative chemotherapy (HIOC) for pleural mesothelioma patients.

During HIOC, a solution of chemotherapy drugs is rinsed through the chest following surgical resection of a malignant pleural mesothelioma tumor in order to kill residual cancer cells and keep new tumors from developing.

One hundred and forty-one patients were enrolled in the trial, which involved escalating the dose of gemcitabine to find the maximum tolerable dose (MTD). After two patients developed Grade 3 leukopenia (a reduction in white blood cells) at 1100 mg/m2 of gemcitabine, researchers set the MTD at 1000 mg/m2 of gemcitabine with 175 mg/m2 of cisplatin.

Median overall recurrence-free survival was 20.3 months among those who had HIOC with gemcitabine following EPP surgery and 10.7 months following lung-sparing P/D surgery.

The report concludes that the cisplatin/gemcitabine HIOC combination “can be administered safely and feasibly in the context of complete surgical resection of malignant pleural mesothelioma by EPP or P/D.” It appears in the latest issue of the Journal of Thoracic Surgery.

Sources:

Gregorc, V, et al, “NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial”, May 9, 2018, Epub ahead of print

Burt, BM, et al, “A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma”, Mary 9, 2018, Journal of THoracic Oncology, Epub ahead of print

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…